UBS/CALL/INNOVENT BIOLOGICS/45/0.02/16.09.24

UBS/CALL/INNOVENT BIOLOGICS/45/0.02/16.09.24 Share Price

Warrant

20007

CH0475710577

Market Closed - Hong Kong S.E. 01:38:12 08/06/2022 pm IST
0.01 ^HKD	-.--%

Current year

-90.29%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart INNOVENT BIOLOGICS, INC.

Chart UBS/CALL/INNOVENT BIOLOGICS/45/0.02/16.09.24

Latest news about INNOVENT BIOLOGICS, INC.

Innovent Announces the New Drug Application of IBI311 has been accepted by the NMPA of China for Thyroid Eye Disease	22/05	AQ
Chinese Regulator Accepts Innovent Biologics' New Drug Application for Thyroid Eye Disease Drug	21/05	MT
Innovent Biologics Announces Oral Presentations at ESMO Plenary and ESMO GI Congress on Clinical Data of IBI363 and IBI343	20/05	AQ
Head-to-head Superiority to High-dose Dulaglutide, Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints	10/05	AQ

More news

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	INNOVENT BIOLOGICS, INC.
Issuer	UBS
	20007
ISIN	CH0475710577
Date issued	15/09/2023
Strike	45 $
Maturity	16/09/2024 (113 Days)
Parity	50 : 1
Emission price	0.25 $
Emission volume	N/A
Settlement	cash
Currency	HKD

Technical Indicators

Highest since issue	0.107 $
Lowest since issue	0.01 $
Spread	- $
Spread %	-.--%

Company Profile

Innovent Biologics Inc is an investment holding company principally engaged in biopharmaceuticals. The Company and its subsidiaries are engaged in research and development of antibody and protein medicine products, sale and distribution of pharmaceutical products, and provision of consultation and research and development services. The Company's main product is Tyvyt (sintilimab injection), which is used to treat relapsed or refractory classical Hodgkinâs lymphoma. The Company's products also include adalimumab biosimilar IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab biosimilar IBI-305 is used to treat metastatic colorectal cancer and advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). Rituximab biosimilar IBI-301 is used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Its products are used in oncology, metabolic, immunology and ophthalmology diseases.

Sector

More about the company